NCT06038526 2026-02-19
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT05641831 2026-01-02
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04789681 2025-12-26
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
Phase 2 Recruiting